 "UCLA, cancer drug")
BDR Pharmaceuticals on Wednesday said it has launched the generic version ofLenvatinib drug for the treatmentof various types of cancers in India.
The generic version of the drug has been launched under the brand name 'Bdfoie' in the country.
Thecapsules are usedfor the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer,BDR Pharma said in a statement.
The results of clinical trials showed encouraging results with safety and efficacy on patients with aggressive tumours, it added.
The drug is priced at Rs 1,620 (4 mg) and Rs 2,970 (10 mg) for a pack of 10 capsules,the statement said.
"By launching cost-effective therapy options we want to mitigate the challenges faced by Indian patients in seeking access to treatment and finding a timely cure for life threatening diseases,"BDR Pharmaceuticals CMDDharmesh Shah said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
